Absolutely fox. However the predictions i have made are based on the most reliable information i can get being someone reporting the number of procedures that required a patch.
The same data base reports some 60 000 + valve procedures for 2013 (an increase from 31000 procedures performed in 2005) but they all seem to be replacements ( no mention of repairs). Furthermore not all valve repairs result in replacement of a valve leaf (sometimes the old leaf is simply
Re modeled ). Without any factual numbers i am hesitent to estimate the proportion of valve procedures that will result in sales of CC.
I would love to think that there is an instant market ready to purchase 60 000 bits of CC each year in the USA, but thats just plain silly.
On a cheerier note, valve repairs is reportedly preferable replacement as it eliminates the coagulation issues that come with valve replacement. CC just may be the product that the world has been waiting for that will see valve repairs a more viable option.
- Forums
- ASX - By Stock
- AVR
- Ann: Admedus expands CardioCel market
Ann: Admedus expands CardioCel market, page-61
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $341.1M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.75 | $72.87K | 4.07K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 29 | $18.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.25 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 124 | 17.930 |
1 | 691 | 17.900 |
1 | 1 | 17.800 |
1 | 26 | 17.740 |
1 | 443 | 17.700 |
Price($) | Vol. | No. |
---|---|---|
18.000 | 354 | 3 |
18.250 | 217 | 3 |
18.300 | 166 | 2 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
Last trade - 15.40pm 15/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online